Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrahydrozoline + glycerin + hypromellose + polyethylene glycol 400
- Development stage
- Unknown
- Lead developer
- KC Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
This is an ophthalmic combination product containing **tetrahydrozoline**, **glycerin**, **hypromellose**, and **polyethylene glycol 400**. Tetrahydrozoline is an imidazoline derivative acting as a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels and providing rapid, temporary relief of ocular redness. Glycerin, hypromellose, and polyethylene glycol 400 are lubricants that relieve dryness, burning, and discomfort by stabilizing and supplementing the tear film. The product is primarily used for symptomatic relief of eye redness, minor irritation, and dryness caused by environmental factors or exposure to irritants. It is available as an over-the-counter eye drop solution[3][1][4].
- Brand names
- WALGREENS MULTI-SYMPTOM RELIEF EYE DROPS
- Other names
- Walgreens Multi-Symptom Relief Eye Drops
02
Targets
ADRA1A (α1A)ADRA2A (α2A)ADRA2C (α2C)
Beyond the preview
Go deeper on tetrahydrozoline + glycerin + hypromellose + polyethylene glycol 400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrahydrozoline + glycerin + hypromellose + polyethylene glycol 400.